Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Combination Therapy With the Proteasome Inhibitor Carfilzomib for the Antibody-Mediated Rejection Diagnosis in Lung Transplantation Trial (PICARD-Lung)

Next Previous
Trial Profile

Combination Therapy With the Proteasome Inhibitor Carfilzomib for the Antibody-Mediated Rejection Diagnosis in Lung Transplantation Trial (PICARD-Lung)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 27 Apr 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carfilzomib (Primary) ; Immune globulin
  • Indications Lung transplant rejection
  • Focus Pharmacodynamics
  • Acronyms PICARD-Lung

    • Most Recent Events

    • 25 Mar 2022 Status changed from recruiting to completed.
    • 25 Mar 2022 The primary endpoint Absolute change in DSA strength, titer, and complement fixation is changed to Number of Participants With a Decrease in Titer of One or More DSA, Number of Participants With a Decrease in DSA Titer, and Number of Participants With an Absence of One or More Previously Positive DSA on Cq1 Assay, according to ClinicalTrials.gov.
    • 01 Jul 2020 Planned End Date changed from 1 Dec 2020 to 1 Dec 2021.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top